This publication summarizes the current understanding of fibrolamellar carcinoma based on a review of currently available literature. It outlines the epidemiology, pathology, and biology of FLC, plus provides a high-level overview of the evidence supporting existing therapies for the disease — including surgical, radiotherapy, interventional radiology and systemic treatments. The full article can be read …
This publication describes the results of the first large scale screening of known drugs and compounds for their effectiveness against FLC. It identified six new PDX lines derived by direct implantation of tumor specimens, both from the liver (one primary and one recurrent tumor) and metastases. These facilitated the first reported large-scale screening of compounds …
This article, published in Nature Reviews Gastroenterology & Hepatology, summarizes the key advances made in understanding the disease since the 2014 discovery that nearly all FLC tumors contain the DNAJB1-PRKACA chimeric fusion transcript. The paper outlines the advances made in understanding the molecular pathways driven by the fusion protein and the potential to identify actionable …
This poster presentation outlines Rush University Medical Center’s experience in treating FLC patients with a gemcitabine-oxaliplatin-lenvatanib (GEMOX-LEN) combination. This study describes the experiences of 16 patients, most of whom had multiple prior surgeries and systemic therapies, who were judged unresectable. The Rush University team chose gemcitabine-oxaliplatin (GEMOX) based on case reports of GEMOX efficacy in …
This on-line discussion focuses on understanding the current role of immunotherapy in treating cancer, explores promising new developments in the field and discusses immunotherapy’s potential for treating FLC. In the recorded event, Mark Furth, FCF’s Scientific Director, moderates a conversation with Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns …
In this video from Rush University Medical Center, Dr. Paul Kent narrates a PowerPoint presentation outlining his team’s experiences in treating patients with FLC.